Source: International Congress 2015 – Multidisciplinary approaches in the personalized care of the ALK + NSCLC patient



Rating:

Share or cite this content

Citations should be made in the following way:
Egbert E.F. Smit (Amsterdam, Netherlands). How novel targeted therapies have changed patient outcomes in ALK+ NSCLC. International Congress 2015 – Multidisciplinary approaches in the personalized care of the ALK + NSCLC patient

Member's Comments

No comment yet.

Related content which might interest you: Bevacizumab shows survival benefit for non-small lung cancer patients who received subsequent pemetrexed treatment but not had a therapeutic effect in clinical practice Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 A preliminary study on targeted therapies in advanced lung cancer patients Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009 A variant in LKB1 gene can predicts the clinical outcomes of chemotherapy in patients with non-small cell lung cancer Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management Year: 2018 ALK- and ROS-1-inhibition: a relevant treatment strategy for lung cancer? Source: International Congress 2014 – Update on lung cancer biology for clinicians Year: 2014 Relapsed NSCLC and SCLC: benefits and limitations of systemic treatments beyond the second line Source: International Congress 2017 – Rational strategies for specific treatment situations in lung cancer Year: 2017 KRAS oncogene in lung cancer: focus on molecularly driven clinical trials Source: Eur Respir Rev 2015; 25: 71-76 Year: 2016 Therapeutic management of ALK+ nonsmall cell lung cancer patients Source: Eur Respir J 2015; 46: 230-242 Year: 2015 Real-life experience of ceritinib in crizotinib-pretreated ALK+ advanced non-small cell lung cancer patients Source: ERJ Open Res, 4 (1) 00058-2017; 10.1183/23120541.00058-2017 Year: 2018 Survival prognosis and target therapy best response in adenocarcinoma lung cancer pts with mutation EGFR gene Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009 Can molecular markers (EGFR, ERCC1) serve as screening parameters for adjuvant chemotherapy decision in early staged non-small cell lung cancer patients? Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases Year: 2010 Novel approaches in metastasised non-small cell lung cancer with a special focus on modern systemic therapies Source: International Congress 2019 – State of the art session: Thoracic oncology Year: 2019 Dynamic monitoring of EGFR mutations in circulating tumor DNA for early detection of drug resistance in NSCLC patients on EGFR-TKI therapy Source: International Congress 2019 – Diagnostic procedures and biology of lung cancer Year: 2019 Can we expect progress from targeted therapy of SCLC? Source: Eur Respir Monogr 2015; 68: 234-246 Year: 2015 Efficacy and prognostic factors of first-line afatinib treatment for the EGFR-mutated non-small cell lung cancer in the real world Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology Year: 2020 Targeted therapies: detrimental treatment for nonsmall cell lung cancer without driver mutations Source: Eur Respir J 2015; 46: 19-21 Year: 2015 Should patients with metastatic NSCLC and poor performance status be treated by chemotherapy? Source: Annual Congress 2007 - Treatment of metastatic nonsmall cell lung cancer in the era of targeted therapies Year: 2007